SG11201804413XA - Recombinant serine proteases - Google Patents
Recombinant serine proteasesInfo
- Publication number
- SG11201804413XA SG11201804413XA SG11201804413XA SG11201804413XA SG11201804413XA SG 11201804413X A SG11201804413X A SG 11201804413XA SG 11201804413X A SG11201804413X A SG 11201804413XA SG 11201804413X A SG11201804413X A SG 11201804413XA SG 11201804413X A SG11201804413X A SG 11201804413XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- leiden
- albinusdreef
- serine protease
- lumc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6443—Coagulation factor XIa (3.4.21.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21027—Coagulation factor XIa (3.4.21.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau IIIIII Hit II EH DID IIIII DEEM II III 1111111111 DID 11111111D It RID IIII (10) International Publication Number WO 2017/091074 Al WIPO I PCT (43) International Publication Date 1 June 2017 (01.06.2017) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (51) International Patent Classification: C12N 9/64 (2006.01) C12N 9/72 (2006.01) C12N 9/74 (2006.01) (21) International Application Number: PCT/NL2016/050833 (22) International Filing Date: 25 November 2016 (25.11.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15196291.7 25 November 2015 (25.11.2015) EP (71) Applicant: ACADEMISCH ZIEKENHUIS LEIDEN [NL/NL]; Albinusdreef 2, 2333 ZA Leiden (NL). (72) Inventors: VERHOEF, Daniel; c/o Einthoven Laboratory of Experimental, Vascular Medicine, Department of Trom- bosis and Hemostasis, LUMC, Albinusdreef 2, 2333 ZA Leiden (NL). REITSMA, Pieter H.; c/o Einthoven Labor- atory of Experimental, Vascular Medicine, Department of Trombosis and Hemostasis, LUMC, Albinusdreef 2, 2333 ZA Leiden (NL). BOS, Mettine H.A.; c/o Einthoven Laboratory of Experimental, Vascular Medicine, Depart- ment of Trombosis and Hemostasis, LUMC, Albinusdreef 2, 2333 ZA Leiden (NL). (74) Agent: JANSEN, C.M.; V.O., Carnegieplein 5, 2517 KJ Den Haag (NL). W O 20 17 /09 107 4 Al (54) Title: RECOMBINANT SERINE PROTEASES (57) : The present invention relates to recombinant proteins comprising serine protease polypeptides that have serine pro - tease activity in the presence of a serine protease inhibitor and that are able to completely or partially reverse a serine protease inhib - itor effect, for example in a subject treated with a serine protease inhibitor. More specifically, described herein are recombinant pro - teins and methods for completely or partially reversing an anti-coagulant effect of a coagulation inhibitor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15196291 | 2015-11-25 | ||
PCT/NL2016/050833 WO2017091074A1 (en) | 2015-11-25 | 2016-11-25 | Recombinant serine proteases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804413XA true SG11201804413XA (en) | 2018-06-28 |
Family
ID=54705420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804413XA SG11201804413XA (en) | 2015-11-25 | 2016-11-25 | Recombinant serine proteases |
Country Status (15)
Country | Link |
---|---|
US (1) | US20180340163A1 (en) |
EP (1) | EP3380610A1 (en) |
JP (1) | JP2018537976A (en) |
KR (1) | KR20180089439A (en) |
CN (1) | CN108463553A (en) |
AU (1) | AU2016358796A1 (en) |
BR (1) | BR112018010603A2 (en) |
CA (1) | CA3006175A1 (en) |
EA (1) | EA201891012A1 (en) |
HK (1) | HK1255343A1 (en) |
IL (1) | IL259532A (en) |
MA (1) | MA43312A (en) |
MX (1) | MX2018006479A (en) |
SG (1) | SG11201804413XA (en) |
WO (1) | WO2017091074A1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US5304482A (en) * | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
GB9216558D0 (en) * | 1992-08-04 | 1992-09-16 | British Bio Technology | Modified proteases |
US7060484B1 (en) * | 1993-11-12 | 2006-06-13 | Gilead Sciences, Inc. | Polypeptides and coagulation therapy |
EP1141263A4 (en) | 1998-09-21 | 2002-08-28 | Lilly Co Eli | Production of soluble recombinant trypsinogen analogs |
TWI393716B (en) | 2009-08-04 | 2013-04-21 | Merck Sharp & Dohme | Heterocyclic compounds as factor ixa inhibitors |
-
2016
- 2016-11-25 CA CA3006175A patent/CA3006175A1/en not_active Abandoned
- 2016-11-25 BR BR112018010603A patent/BR112018010603A2/en not_active Application Discontinuation
- 2016-11-25 EA EA201891012A patent/EA201891012A1/en unknown
- 2016-11-25 SG SG11201804413XA patent/SG11201804413XA/en unknown
- 2016-11-25 MA MA043312A patent/MA43312A/en unknown
- 2016-11-25 CN CN201680078249.1A patent/CN108463553A/en active Pending
- 2016-11-25 WO PCT/NL2016/050833 patent/WO2017091074A1/en active Application Filing
- 2016-11-25 KR KR1020187017489A patent/KR20180089439A/en unknown
- 2016-11-25 JP JP2018527905A patent/JP2018537976A/en active Pending
- 2016-11-25 EP EP16834290.5A patent/EP3380610A1/en not_active Withdrawn
- 2016-11-25 AU AU2016358796A patent/AU2016358796A1/en not_active Abandoned
- 2016-11-25 MX MX2018006479A patent/MX2018006479A/en unknown
- 2016-11-25 US US15/777,963 patent/US20180340163A1/en not_active Abandoned
-
2018
- 2018-05-22 IL IL259532A patent/IL259532A/en unknown
- 2018-11-13 HK HK18114479.1A patent/HK1255343A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016358796A1 (en) | 2018-06-21 |
MA43312A (en) | 2018-10-03 |
CA3006175A1 (en) | 2017-06-01 |
CN108463553A (en) | 2018-08-28 |
JP2018537976A (en) | 2018-12-27 |
KR20180089439A (en) | 2018-08-08 |
MX2018006479A (en) | 2019-01-28 |
US20180340163A1 (en) | 2018-11-29 |
EA201891012A1 (en) | 2019-01-31 |
IL259532A (en) | 2018-07-31 |
WO2017091074A1 (en) | 2017-06-01 |
BR112018010603A2 (en) | 2018-11-13 |
HK1255343A1 (en) | 2019-08-16 |
EP3380610A1 (en) | 2018-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201806639VA (en) | New streptococcal proteases | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201408459VA (en) | Purification of virus like particles | |
SG11201810594RA (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection | |
SG11201805229YA (en) | Means and methods for treating hbv | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201909927RA (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
SG11201807972YA (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
SG11201906301UA (en) | Methods of manufacture of nut flours and formulations for oral immunotherapy | |
SG11201909606RA (en) | Probiotic molecules for reducing pathogen virulence | |
SG11201803642WA (en) | Bacteria-based protein delivery | |
SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |